By Counterforce Health Team in Prolastin-C (alpha1-proteinase inhibitor) —

How to Get Prolastin-C (Alpha1-Proteinase Inhibitor) Covered by Aetna (CVS Health) in Georgia: PA Forms, Appeals Timeline & Scripts

Quick Answer: Prolastin-C Coverage by Aetna in Georgia

Aetna requires prior authorization for Prolastin-C (alpha1-proteinase inhibitor) and classifies it as non-formulary on most 2024 commercial plans. To get coverage, you need: Pi*ZZ genotype confirmation, serum AAT level below 57 mg/dL, post-bronchodilator FEV₁ between 25-80% predicted, and a formulary exception request since Aralast NP and Glassia are preferred alternatives. Submit via Aetna's Alpha1-Proteinase Inhibitor precertification form (fax 888-267-3277). If denied, you have 180 days to appeal internally, then 30 days for Georgia's external review through the Department of Insurance.

First step today: Contact your pulmonologist to gather Pi*ZZ genotype results and recent spirometry, then call Aetna at 866-752-7021 to verify your plan's specific formulary status.

Table of Contents

Plan Types & Coverage Implications

Your Aetna plan type determines how Prolastin-C authorization works. Commercial plans (employer or individual marketplace) typically require prior authorization and may have formulary restrictions. Medicare Advantage plans follow Medicare Part B guidelines, where Prolastin-C and Zemaira are often preferred over Glassia and Aralast NP.

For HMO plans, ensure your pulmonologist is in-network before starting the PA process. PPO plans offer more flexibility but may still require authorization for specialty infusions. Check your member portal or call the number on your insurance card to confirm your specific plan type and formulary.

Tip: Georgia residents with employer plans should also check if your company offers a specialty drug benefit through CVS Specialty, which can streamline the approval process.

Formulary Status & Preferred Alternatives

Prolastin-C is non-formulary on most 2024 Aetna commercial formularies, with Aralast NP and Glassia designated as preferred alternatives. This means you'll need to submit a formulary exception request documenting why preferred agents are inappropriate.

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for all alpha1-proteinase inhibitors Clinical Policy Bulletin #0145 Aetna Policy
Formulary Status Non-formulary (exception needed) 2024 formulary documents Formulary Navigator
Step Therapy Must try preferred alternatives first Medicare Part B preferred drug list 2026 Part B List
Site of Care Home infusion preferred after initial doses Site-of-care policy Aetna Policy

Medical Necessity Requirements

Aetna requires all of the following criteria for Prolastin-C coverage:

Diagnosis & Laboratory Evidence

  • Confirmed severe hereditary AAT deficiency with Pi*ZZ genotype (or equivalent severe variant like Pi*Z null)
  • Serum AAT level below 57 mg/dL via quantitative testing within 12 months
  • Documentation of emphysema or COPD (ICD-10 codes E88.01 plus J43.x/J44.x)

Pulmonary Function Requirements

  • Post-bronchodilator FEV₁ between 25% and 80% predicted
  • Evidence of fixed airflow obstruction (FEV₁/FVC <0.7)
  • Spirometry performed to ATS/ERS standards within 6 months

Patient Status

  • Adult (≥18 years old)
  • Non-smoker or enrolled in intensive smoking cessation program
  • No contraindications to alpha1-proteinase inhibitor therapy
Note: Unlike other tests, genotype documentation doesn't expire and can be submitted from any previous testing.

Prior Authorization Process

Step-by-Step: Fastest Path to Approval

  1. Gather Required Documentation (Patient/Clinic)
    • Pi*ZZ genotype confirmation
    • Recent serum AAT level (<57 mg/dL)
    • Spirometry results (FEV₁ 25-80% predicted)
    • CT chest showing emphysema
    • Smoking cessation documentation
  2. Complete PA Form (Clinic)
  3. Submit Formulary Exception (Clinic)
    • Document why Aralast NP/Glassia are inappropriate
    • Include previous intolerance, contraindications, or inadequate response
    • Reference patient stability on Prolastin-C if applicable
  4. Track Timeline (Patient/Clinic)
    • Standard reviews: 3-15 business days
    • Expedited reviews: 72 hours
    • Formulary exception reviews: 15 business days
  5. Follow Up (Patient)
    • Call 866-752-7021 for status updates
    • Request peer-to-peer review if initial denial

Specialty Pharmacy Network

Aetna directs Prolastin-C prescriptions through CVS Specialty (Accredo) via the Prolastin Direct Program. This program provides:

  • Insurance verification and prior authorization support
  • Home infusion coordination by alpha-1 trained nurses
  • 24/7 pharmacist support and supplies delivery
  • Flexible administration sites (home, work, infusion center)

After your prescription is written, contact the Prolastin Direct Program for automatic enrollment and 24-hour setup. The program handles insurance reviews annually and confirms home infusion eligibility.

Tip: Georgia residents can use Aetna's DocFind tool to locate CVS Specialty infusion sites if home administration isn't suitable.

Cost-Share Basics

Prolastin-C is typically covered under your medical benefit (not pharmacy) due to IV infusion requirements. This means:

  • Deductible applies: You'll pay the full cost until your annual deductible is met
  • Coinsurance follows: After deductible, you pay a percentage (typically 10-30%)
  • Out-of-pocket maximum: Your costs stop once you reach your plan's annual limit

For home infusions, Aetna recognizes HCPCS code S9346 which covers administration, pharmacy coordination, supplies, and equipment (drugs and nursing billed separately).

Counterforce Health helps patients navigate these complex coverage requirements by turning insurance denials into targeted, evidence-backed appeals that align with payer policies and procedural requirements.

Appeals Process in Georgia

If Aetna denies your Prolastin-C request, Georgia law provides a structured appeals process:

Internal Appeals (180 days to file)

  • Level 1: Submit within 180 days of denial; Aetna decides in 30 days (72 hours if urgent)
  • Level 2: Automatic if Level 1 denied; decided in 30 days by different reviewer
  • Submit via Aetna member portal, phone (number on ID card), or mail

External Review (30 days to file)

After exhausting internal appeals, Georgia residents can request external review through the Georgia Department of Insurance:

  • Timeline: File within 30 days of final internal denial
  • Process: Contact Georgia DOI Consumer Services at 1-800-656-2298
  • Decision: Independent physicians review within 45 days
  • Cost: Free for consumers
  • Outcome: Binding on Aetna if approved
Important: Georgia's 30-day external review deadline is stricter than some other states. Don't delay after receiving your final internal denial.

Common Denial Reasons & Solutions

Denial Reason Required Documentation Georgia-Specific Tip
Missing genotype Pi*ZZ or severe variant confirmation Submit any previous genetic testing; doesn't expire
Inadequate lung function FEV₁ 25-80% predicted, post-bronchodilator Request pulmonology consultation if borderline
Non-formulary status Formulary exception request Document contraindications to Aralast NP/Glassia
Step therapy Prior trial/failure proof Out-of-state trials count; gather pharmacy records
Site of care Home infusion preference Request medical necessity for facility-based care

Clinician Corner: Medical Necessity Letters

When writing medical necessity letters for Prolastin-C, include these essential elements:

Clinical Documentation Checklist

  • Diagnosis: Severe hereditary AAT deficiency with emphysema (ICD-10 E88.01, J43.x)
  • Genotype: Pi*ZZ or equivalent severe variant with date of testing
  • Laboratory: Serum AAT <57 mg/dL within 12 months
  • Pulmonary Function: Post-bronchodilator spirometry showing FEV₁ 25-80% predicted
  • Imaging: CT chest demonstrating panacinar or basilar emphysema
  • Treatment History: Previous therapies tried, failed, or contraindicated
  • Clinical Rationale: Why Prolastin-C is medically necessary vs. alternatives

Key Guideline References

Reference Aetna's Clinical Policy Bulletin #0145 and emphasize FDA-approved indication for "chronic augmentation therapy in adults with emphysema due to severe AAT deficiency."

Patient Scripts & Templates

Script: Calling Aetna for PA Status

"Hi, I'm calling to check the status of a prior authorization for Prolastin-C. My member ID is [number]. The PA was submitted on [date] by Dr. [name]. Can you tell me if additional information is needed and when I can expect a decision?"

Script: Requesting Expedited Review

"My doctor says delaying Prolastin-C treatment could worsen my lung function. I'd like to request an expedited review of my prior authorization. What documentation do you need from my physician to process this urgently?"

FAQ

How long does Aetna prior authorization take in Georgia? Standard reviews take 3-15 business days, while expedited reviews are completed within 72 hours if your physician documents medical urgency.

What if Prolastin-C is non-formulary on my plan? Submit a formulary exception request documenting why preferred alternatives (Aralast NP, Glassia) are inappropriate due to contraindications, previous intolerance, or inadequate response.

Can I request an expedited appeal? Yes, if your physician documents that delaying treatment poses serious health risks. Contact Aetna immediately and request expedited processing.

Does step therapy apply if I've failed treatments outside Georgia? Yes, prior therapy failures from other states count toward step therapy requirements. Gather pharmacy records and physician notes documenting the trials and outcomes.

What happens if my external review is denied? Georgia's external review decision is binding on Aetna. If denied, you may have limited options except to try again with additional medical evidence or explore legal consultation.

How do I find CVS Specialty locations in Georgia? Use Aetna's DocFind tool or contact CVS Specialty directly at 1-813-745-7354 for infusion site options.

From our advocates: We've seen cases where patients with borderline FEV₁ readings (just above 80% predicted) initially faced denials, but successful appeals included documentation of disease progression, increased exacerbation frequency, and functional decline despite optimal bronchodilator therapy. The key was demonstrating clinical deterioration trends rather than relying on a single spirometry result.

Counterforce Health specializes in helping patients, clinicians, and specialty pharmacies overcome insurance barriers for complex medications like Prolastin-C. Our platform analyzes denial letters and plan policies to create targeted appeals that address specific payer requirements, pulling the right clinical evidence and weaving it into compelling cases that meet procedural standards. By understanding exactly what insurers like Aetna look for in alpha-1 antitrypsin deficiency cases, we help turn denials into approvals while saving clinicians time and reducing patient stress.

Sources & Further Reading

This information is for educational purposes only and does not constitute medical advice. Always consult with your healthcare provider and insurance company for personalized guidance. For assistance with insurance appeals in Georgia, contact the Georgia Department of Insurance Consumer Services at 1-800-656-2298 or visit oci.ga.gov.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.